Lung transplantation: better survival results after graft pretreatment with concanavalin A or chondroitin sulfate.
Pretreatment of the lung graft with concanavalin A (Con A) or chondroitin sulfate (CIS) was used to modify the lung allograft response after transplantation into moderately immunosuppressed (low doses of azathioprine and prednisone) recipients. Significant (p less than 0.05) prolongation of survival was observed after graft pretreatment. Pneumonia and rejection were the most frequent causes of death for all groups of dogs. However, only 3 out of 6 animals from each of the groups with pretreated grafts died of pneumonia or rejection, whereas 5 of the 6 animals in the control group died of these causes. Furthermore, when rejection occurred in the dogs with lung grafts pretreated with Con A or CIS, it was considerably delayed compared with the controls. Partial pressure of arterial oxygen, chest roentgenograms, and lung histology were good indicators of lung viability after transplantation.
D000818:Animals; D002807:Chondroitin / Q000031:analogs & derivatives*; D002809:Chondroitin Sulfates / Q000494:pharmacology*; D003208:Concanavalin A / Q000494:pharmacology*; D004285:Dogs; D005260:Female; D006084:Graft Rejection / Q000187:drug effects*; D008168:Lung / Q000000981:diagnostic imaging / Q000473:pathology; D016040:Lung Transplantation; D008297:Male; D011014:Pneumonia / Q000517:prevention & control; D011183:Postoperative Complications / Q000517:prevention & control; D011859:Radiography; D014184:Transplantation, Homologous / Q000379:methods* / Q000401:mortality
D003208:Concanavalin A; D002807:Chondroitin; D002809:Chondroitin Sulfates